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mechanisms, mainly in disease development, are quite well known, a comprehensive understanding of
TNF-฀ signaling in the failing heart is still incomplete. Published data identify pathogenic and cardio-
protective mechanisms of TNF-฀ in the affected heart and highlight the differential role of two TNF-฀
receptors pointing to the complexity of the TNF-฀ signaling. In the light of these findings, it seems that
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be more specific and selectively block pathogenic mechanisms. To this aim, more research is needed to
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Abstract: Heart disease is a leading cause of death with unmet clinical needs for targeted treatment
options. Tumor necrosis factor alpha (TNF-α) represents a master pro-inflammatory cytokine that
plays an important role in many immunopathogenic processes. Anti-TNF-α therapy is widely used in
treating autoimmune inflammatory disorders, but in case of patients with heart disease, this treatment
was unsuccessful or even harmful. The underlying reasons remain elusive until today. This review
summarizes the effects of anti-TNF-α treatment in patients with and without heart disease and
describes the involvement of TNF-α signaling in a number of animal models of cardiovascular diseases.
We specifically focused on the role of TNF-α in specific cardiovascular conditions and in defined
cardiac cell types. Although some mechanisms, mainly in disease development, are quite well known,
a comprehensive understanding of TNF-α signaling in the failing heart is still incomplete. Published
data identify pathogenic and cardioprotective mechanisms of TNF-α in the affected heart and highlight
the differential role of two TNF-α receptors pointing to the complexity of the TNF-α signaling. In the
light of these findings, it seems that targeting the TNF-α pathway in heart disease may show therapeutic
benefits, but this approach must be more specific and selectively block pathogenic mechanisms. To this
aim, more research is needed to better understand the molecular mechanisms of TNF-α signaling in the
failing heart.
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1. Introduction
Heart disease refers to a group of diseases characterized by the affected function of the heart muscle.
Epidemiologic data suggest that heart disease is a leading cause of death in the world. Heart failure
affects 26 million people worldwide and causes 1 million annual hospitalizations in the United States
and Europe [1]. Insufficient blood supply of the heart muscle by coronary arteries, which is termed
coronary artery disease, represents the most common cause of heart disease. Extended ischemia in the
myocardium is a life-threating condition that can lead to myocardial infarction or sudden cardiac death.
Aberrant or impaired cardiac function (heart failure) can also develop in the absence of coronary artery
disease. Such non-ischemic heart disease is a consequence of pathological changes in the structure
of the cardiac muscle. In case of heart failure, the heart is unable to efficiently pump the blood due
to ineffective muscle contraction (systolic heart failure) or relaxation (diastolic heart failure). From a
clinical point of view, the type of heart failure depends on the left ventricular ejection fraction (LVEF)
parameter. For LVEF < 40%, systolic heart function is impaired, and this condition is referred to as heart
failure with reduced ejection fraction (HFrEF). Diastolic heart failure patients are often characterized
by LVEF > 50% (or sometimes >40%); therefore, this type of heart failure is currently defined as heart
failure with preserved ejection fraction (HFpEF). Both HFrEF and HFpEF patients show reduced life
expectancy [2,3].
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Inflammation plays an important role in the progression of many types of cardiovascular disease.
On the one hand, the systemic inflammatory condition enhances atherogenesis, leading to coronary
artery disease, but it also can promote the development of diastolic heart failure. On the other hand,
cardiac inflammation occurs in post-ischemic myocardial events, and in more rare cases, it develops as
a response to non-ischemic cardiac injury that often causes pathogenic changes in the cardiac tissue
resulting in systolic dysfunction [4]. Thus, anti-inflammatory treatment has been suggested to protect
the heart and cardiovascular system [5].
Tumor necrosis factor α (TNF-α) represents one of the most potent pro-inflammatory cytokines,
and therefore, it was selected as the first target in the cytokine-targeted approach. Currently, TNF-α
inhibitors are clinically used anti-inflammatory drugs to treat mainly patients with systemic inflammatory
diseases. Roughly 1 million patients receive this type of treatment, and TNF-α antagonists are currently
the most profitable class of drugs in the world, accounting for 25 billion US dollars in sales annually [6].
In case of heart failure, clinical data indicated that TNF-α inhibitors were not effective and even could
worsen disease outcomes. However, the reasons of these disappointing results remain elusive.
2. TNF-α Biosynthesis
In humans, TNF-α is encoded by the TNFA gene located on chromosome 6 and shares locus with major
histocompatibility complex (MHC) class II genes, which plays a central role in antigen presentation [7].
The TNFA gene consists of 200 nucleotide promoters with binding sites for several transcription factors,
resulting in a high plasticity of transcription and responsiveness to various types of stimuli, which also
vary between cell types [8].
At the post-transcript stage, the biosynthesis of TNF-α is controlled mainly through the competitive
binding of the mRNA 3′ AU-rich untranslated region by RNA-binding proteins tristetraprolin (TTP)
and stabilizing factor human antigen R (HuR). The dephosphorylated form of TTP effectively binds to
mRNA and degrades it. The phosphorylation of TTP weakens its affinity to mRNA preventing its
degradation. This allows the binding of HuR to mRNA and enables a more efficient translation of TNFA
transcripts. Pro-inflammatory stimuli, such as lipopolysaccharide (LPS), regulate the activity of TTP
and the translocation of HuR from the nucleus to cytoplasm, thereby enhancing TNF-α biosynthesis.
TTP activity is regulated by p38 mitogen-activated protein kinases (MAPK), which controls TTP
target genes at the post-transcriptional level and the binding of nuclear factor kappa B (NF-κB) to the
promoter of TTP, which positively regulates its translation [9–11]. The deficiency of TTP in mice leads
to increased TNF-α production that results in growth retardation, cachexia, arthritis, and autoimmune
response [12]. The biosynthesis of TNF-α is regulated by a number of inflammatory mediators such as
LPS, interleukin (IL)-1β, IL-6, interferon gamma (IFN-γ), tissue trauma, or hypoxia [13–15].
Upon translation, TNF-α is synthesized as a 17 kDa type II (i.e., possessing a single, uncleavable
transmembrane segment, which anchors the protein in a cell membrane with the C-terminal end
oriented toward cytoplasm) transmembrane protein. This membrane form of TNF-α (mTNF-α) can
function as a ligand. The extracellular domain of mTNF-α can be cleaved by TNF-α cleaving enzyme
(TACE; ADAM17) and released as soluble TNF-α (sTNF-α) [16]. mTNF-α and sTNF-α assemble as
noncovalently bound homotrimers and in this form exert their biological functions [17].
3. TNF-α Receptors
TNF-α represents a ligand for two types of TNF-α receptors (TNFRs), namely TNFR1 (CD120a, p55)
and TNFR2 (CD120b, p75). TNFRs represent single transmembrane glycoproteins with extracellular
TNF-α binding domains characterized by four tandem-repeated cysteine-rich motifs [18]. TNFRs are
typically located on the cell membrane, but they can be shed and released in soluble forms with the
ability to bind and neutralize the activity of circulating sTNF-α. In the body, most cells constitutively
express TNFR1. In contrast, the expression of TNFR2 is often induced by pro-inflammatory factors
and is restricted mainly to immune cells, but it can be also upregulated by endothelial cells or
cardiomyocytes [19,20]. The activation of TNFR1 or TNFR2 depends on the bioavailability of the
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soluble and membrane-bound forms of TNF-α. sTNF-α shows a far greater affinity to TNFR1, whereas
TNFR2 is activated mainly by mTNF-α [21]. The stimulation of TNFR1 and TNFR2 activates a distinct
molecular response resulting in different effector outputs in the affected cell. Furthermore, mTNF-α
is capable of transmitting reverse signaling and therefore must be considered as a receptor, too [22].
In this case, TNFRs (membrane and soluble) serve as ligands for mTNF-α. The mTNF-α reverse













Figure 1. Overview of tumor necrosis factor-α (TNF-α) downstream signaling pathway mediated by
two TNF-α receptors, TNFR1 and TNFR2, and by membrane form of TNF-α (mTNF-α) reverse signaling.
3.1. TNFR1 Signaling
In the presence of the ligand, TNFR1 recruits a number of adaptor proteins including TNFR-associated
death domain (TRADD), TNF-α receptor associated factor 2 (TRAF2), receptor-interacting protein (RIP)
kinase, inhibitors of apoptosis proteins (IAPs), Fas-associated death domain (FADD) and MAPK activating
death domain (MADD) [19,21]. The newly formed TNFR1/TRADD/TRAF2/RIP/IAPs complex activates
MAPKs, mainly c-Jun N-terminal kinase (JNK) and the p38 isoforms, and inhibitor of kappa B (IκB)
kinases (IKKs). MAPKs transduce a signal into the nucleus through activation protein-1 (AP-1) and
other transcription factors that bind to the specific DNA motifs of the target genes. IKKs activate the
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NF-κB response by degrading the IκB complex and thus releasing the p50 subunit, which translocates
to the nucleus and directly regulates gene expression. These MAPK- and IKK-dependent responses
contribute mainly to pro-inflammatory cytokine production and cell survival, but they also mediate
other processes [19,23]. Alternatively, TNFR1 can be internalized, and due to its intracellular death
domain, it can form the TNFR1/TRADD/FADD complex with pro-caspase-8. Activated caspase-8 initiates
a proteolytic cascade causing cell apoptosis. Of note, TNF-α-induced apoptosis is also mediated by
MAPK/JNK [24]. Furthermore, TNFR1 can induce necroptosis through mitochondrial fission. Necroptosis
is independent of other caspases, and the process occurs under conditions of caspase-8 inhibitor or
depletion. TNF-α mediated necrosome formation critically depends on RIP1, RIP3, and mixed lineage
kinase domain like (MLKL) pseudokinase [25,26].
3.2. TNFR2 Signaling
Unlike TNFR1, TNFR2 lacks the intracellular death domain and is unable to bind TRADD and
initiate caspase-mediated apoptosis. Instead, activated TNFR2 recruits adaptor proteins TRAF2 and
IAPs, activating the canonical NF-κB signaling through IKK. In addition, TNFR2, TRAF2, and IAPs
form a complex with NF-κB-inducing kinase (NIK). As a result, NIK is released from the complex and
activated. Active NIK induces the non-canonical NF-κB pathway through IKKα that ultimately produces
a transcriptionally active p52 subunit [27]. TNFR2 can also activate phosphatidylinositol-3-kinase (PI3K)-
dependent signaling. In this pathway, activated PI3K phosphorylates protein kinase B, also known
as Akt, which in turn modulates several downstream effectors [28]. TNFR2-mediated activation of
the canonical and non-canonical NF-κB and PI3K/Akt pathways typically promotes cell proliferation
and survival. In cells expressing both TNFRs, the cross-talk between TNFR1 and TNFR2 may occur,
which is mediated by TRAF2 [19,29]. As prolonged TNFR2 activation leads to TRAF2 degradation, this
negatively regulates transcription factors and the immune response but enhances TNFR1-dependent
caspase-mediated apoptosis and necroptosis [21,30].
3.3. mTNF-α Reverse Signaling
mTNF-α acts not only as a ligand for TNFRs triggering forward signaling in the target cells but
also transduces a reverse signaling back to the mTNF-α expressing cell. Physiologically, the mTNF-α
reverse signaling is triggered by TNFR2 expressed by the neighboring cells [31]. Furthermore, soluble
TNFRs (mainly TNFR2) or even selected anti-TNF-α antibodies can activate the mTNF-α reverse
signaling [32,33]. The intracellular domain of mTNF-α shows no kinase activity; however, the binding
of TNFR to mTNF-α can activate MAPKs JNK and p38 signaling and the downstream transcriptional
activities in the nucleus. mTNF-α reverse signaling regulates the production of certain inflammatory
cytokines, but it is also involved in the modulation of other immune processes [34]. It should be noted
that the role and mechanisms of mTNF-α reverse signal transduction are not well understood.
4. Anti-TNF-α Therapy and Cardiovascular Diseases in Humans
In the 20th century, TNF-α has been recognized as the key pro-inflammatory cytokine in humans.
This led to the development of the first cytokine-targeted therapy with etanercept approved by the
Food and Drug Administration (FDA) in 1998. Anti-TNF-α therapy has revolutionized the treatment
of autoimmune inflammatory diseases by offering an alternative for non-specific immunosuppressive
drugs, which cause multiple adverse effects for a long-term use [35]. To date, five FDA-approved
TNF-α inhibitors are being used in routine clinical practice to treat patients with rheumatoid and
psoriatic arthritis, psoriasis, ankylosing spondylitis, or Crohn’s disease. TNF-α inhibitors represent the
fusion protein of TNF-α receptors linked to the Fc region of human antibody (etanercept) or chimeric
(infliximab), fully human (adalimumab and golimumab), or modified human (certolizumab–pegol)
anti-TNF-α antibodies [36]. Although all these inhibitors neutralize TNF-α bioactivity, their therapeutic
effect may vary [37,38].
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The positive effects of anti-TNF-α therapy in autoimmune inflammatory diseases encouraged
testing its therapeutic value in patients with systolic heart failure. These patients are characterized by
elevated plasma levels of TNF-α and other pro-inflammatory cytokines [39–42], and improvement of
their cardiac functions has been associated with decreasing TNF-α levels [43]. In fact, heart failure
patients show also elevated cardiac TNF-α levels associated with dynamic changes in TNFR1 and
TNFR2 expression [44]. Furthermore, genetic studies suggested that polymorphism in the TNFA gene
was associated with increased risk of coronary heart disease development [45] and in case of coronary
heart disease with increased risk of gastrointestinal complications [46]. Pilot studies suggested that a
higher dose of etanercept increased the ejection fraction and quality-of-life scores [47,48], as well as
improved systemic endothelial vasoreactivity in patients with advanced heart failure [49]. Nonetheless,
randomized, double-blind, placebo-controlled studies failed to prove the therapeutic effect of etanercept
in heart failure patients with reduced ejection fraction. In fact, the RECOVER (Research into Etanercept:
Cytokine Antagonism in Ventricular Dysfunction) and RENAISSANCE (Randomized Etanercept North
American Strategy to Study Antagonism of Cytokines) clinical trials were terminated early due to
a general lack of improvement in composite clinical score and due to the dose-dependent toxicity
observed in some patients [50]. Furthermore, the ATTACH (Anti-Tnf alpha Therapy Against Chronic
Heart failure) study showed that high doses of infliximab in HFrEF patients increased the risk of death
or heart failure-related hospitalization [51]. The injection of a single high dose of etanercept did not
improve outcomes of patients following acute myocardial infarction [52]. In conclusion, continuous
anti-TNF-α therapy in patients with systolic heart failure show no evident benefits and may even be
harmful and exacerbate the disease. Consequently, the use of TNF-α inhibitors is not recommended
for HFrEF patients.
Unlike for HFrEF patients, a long-term anti-TNF-α therapy in patients with autoimmune inflammatory
diseases is generally not harmful, and it may even protect from enhanced cardiovascular complications
and cardiovascular death [53,54]. Although heart failure cases have been reported in patients treated
with TNF-α inhibitors [55], the risk of new onset of heart failure in patients under age 50 receiving
etanercept or infliximab is low [56]. Anti-TNF-α treatment is most commonly used to treat rheumatoid
arthritis. Importantly, these patients are characterized by a more rapid development of subclinical
changes in diastolic function [57], and in case of incident heart failure, they are more likely to show the
HFpEF phenotype [58]. In fact, rheumatoid arthritis patients with preserved left ventricular function
treated with infliximab showed improvement in cardiac function [59] and decreased the left ventricular
torsion [60]. A growing body of evidence suggests that anti-TNF-α therapy could effectively protect
from the development of vascular diseases and atherosclerosis in particular. Standard anti-TNF-α
treatment employed in treating rheumatoid arthritis has been demonstrated to decrease levels of
soluble endothelial adhesions molecules [61] as well as improve arterial stiffness [62] and endothelial
functions [63]. The use of TNF-α antagonists has been associated with a decreased risk of myocardial
infarction [64] and development of acute coronary syndrome [65] pointing to anti-TNF-α treatment as
an effective anti-atherosclerotic therapy in rheumatoid arthritis. In line with these data, large cohort
clinical studies reported the unchanged or reduced overall cardiovascular-related death of rheumatoid
arthritis patients receiving TNF-α inhibitors [66–69]. Importantly, in rheumatoid arthritis, anti-TNF-α
therapy protects from the development of ischemic cardiac events, but it shows no cardioprotective
effects in the post-ischemic heart [64]. Noteworthy, anti-TNF-α therapy in elderly rheumatoid arthritis
patients might exacerbate heart failure and reduce survival [70].
Psoriasis represents another autoimmune inflammatory disease associated with increased serum
levels of TNF-α [71]. Similarly to other systemic inflammatory diseases, psoriasis patients are at increased
risk of developing cardiovascular diseases [72]. In psoriasis, patients treated with adalimumab showed
improvement in vascular functions [73]. A large retrospective cohort study has demonstrated a significantly
reduced incidence of myocardial infarction in psoriasis patients receiving TNF-α inhibitors [74]. In line
with these findings, the use of TNF-α inhibitors in psoriasis lowered the occurrence of major cardiovascular
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events [75]. Reductions of cardiovascular events due to treatment with TNF-α inhibitors were also
observed in ankylosing spondylitis and psoriatic arthritis [76,77].
Summarizing, in the light of published clinical data (summarized in the Table 1), anti-TNF-α
treatment seems to reduce the risk of cardiovascular episodes mainly by inhibiting systemic inflammation
and thereby suppressing the development of atherosclerosis and ischemic events. On the other hand,
in the failing heart, TNF-α plays more of a cardioprotective role, but the mechanism remains unknown.
Table 1. Effects of anti-TNF-α treatments on cardiovascular outcomes in heart failure and in systemic
inflammatory disease patients.
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study (8845 patients) Psoriasis
At least 2 months of
adalimumab, etanercept,
or infliximab treatment
Reduced risk of myocardial





150 days of adalimumab,
etanercept, infliximab,
or methotrexate treatment
Treatment with TNF-α inhibitors
was shown to reduce overall











(at least 1 year) with
TNF-α inhibitors
Continuous use of TNF-α inhibitors
reduced the incidence of major
cardiovascular events in comparable
manner in all studied diseases
[76]
Multi-center comparative
study (319) Psoriatic arthritis
Long-term treatment (2–3
years) with TNF-α inhibitors
Reduced atherosclerosis in men,
but not women, receiving TNF-α
inhibitors. Reduction of vascular
inflammation in both sexes
[77]
LV: left ventricle, NT-proBNP: N-terminal prohormone of brain natriuretic peptide, DMARD-disease-modifying
antirheumatic drugs.
5. TNF-α in Animal Models of Cardiovascular Diseases
Results of anti-TNF-α treatments in patients with heart failure or with autoimmune inflammatory
diseases demonstrated the relevance and a dual role of TNF-α in cardiovascular diseases in humans.
However, these clinical data are insufficient to elucidate the underlaying mechanisms. Animal models
of cardiovascular diseases, on the other hand, can be used to specifically define the role of gene
of interest and to study cellular and molecular mechanisms. In the case of TNF-α signaling, there
is a number of available transgenic mouse models allowing for the systemic or cell type-specific
overexpression or genetic knockdown of selected components of the TNF-α pathway. The results of
these animal studies are summarized in the Table 2. A growing body of experimental data confirmed a
dual role of TNF-α and pointed to the opposing effects of TNFR1 and TNFR2. Thus, experimental data
from transgenic mouse models might explain the failure of clinical application of anti-TNF-α inhibitors
in heart failure patients. Prospectively, these data suggest that targeting TNFRs, rather than TNF-α,
with selective agonists or antagonists might represent a more promising cardioprotective strategy in
the post-ischemic heart.
5.1. TNF-α in Gain-of-Function Approaches
A gain-of-function approach is based on the overexpression of the gene of interest in a cell or
in an organism and represents one strategy to study its function. A popular knock-in mice model
non-specifically overexpressing human TNF-α shows high TNF-α production mainly in synovial
fibroblasts and in endothelial cells (without evident effects in other cell types) and develops severe
erosive arthritis [78,79]. Therefore, these mice are used as a mouse model of rheumatoid arthritis. Instead,
transgenic mice overexpressing TNF-α in cardiomyocytes are considered as a better model to address the
role of TNF-α in the heart. An initial study showed that the cardiac-restricted overexpression of TNF-α
caused lethal myocarditis with diffuse lymphohistiocytic infiltrates and interstitial edema that led to
cardiac death at the age of 7–11 days [80]. In contrast, in other cardiac-restricted TNF-α overexpressing
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models (TNF1.6 and MHCsTNF strains), most of the transgenic mice survived and developed mild
inflammation and dilated cardiomyopathy phenotype with cardiac tissue remodeling as well as systolic
and diastolic dysfunction associated with atrial and ventricular arrhythmias [81–83]. Mathematical
modeling suggested that the reentrant arrhythmias spontaneously occurring in these mice are caused
by a reduced intercellular coupling [84]. Yet, it needs to be noted that cardiac tissue levels of TNF-α in
these models were elevated up to 200-fold comparing native myocardium. The pathogenic effect caused
by cardiac-restricted TNF-α overexpression depended mainly on the TNFR1 signaling. Accordingly, left
ventricular dysfunction was preserved by the adenoviral-mediated expression of soluble TNFR1 [83],
and the genetic deletion of Tnfrsf1a (gene encoding TNFR1) improved cardiac functions and completely
protected from cardiac death [85]. On the contrary, Tnfrsf1b (gene encoding TNFR2) genetic deficiency
exacerbated heart failure and increased the lethality of TNF-α overexpressing mice pointing to the
cardioprotective role of TNFR2 [85]. Interestingly, the overexpression of non-cleavable mTNF-α in
cardiomyocytes led to a concentric cardiac hypertrophy phenotype without evidence of myocarditis
or systolic dysfunction [86]. This may suggest that in the TNF-α overexpressing heart, the mTNF-α
reverse signaling regulates different processes than TNFR1 and TNFR2.
5.2. Atherosclerosis and Ischemic Heart Disease Models
Atherosclerosis is a pathogenic condition of arteries characterized by the development of atherosclerotic
plaques. A rupture of atherosclerotic plaques and the subsequent blood clot formation can cause
life-threatening ischemic events, such as myocardial infarction or sudden cardiac death. In a typical
clinical scenario of myocardial infarction, atherosclerotic plaque rupture and the subsequent thrombosis
blocks blood flow in larger coronary arteries, causing an ischemic condition in the myocardium and
death of cardiomyocytes. Myocardial infarct size depends on the time and the extent of ischemia as
well as the subsequent inflammatory response. In animal models, myocardial infarction is typically
performed in non-atherosclerotic condition.
5.3. Atherosclerosis
Experimental atherosclerosis is typically induced by feeding animals an atherogenic high-fat,
high-cholesterol diet over at least 3 months. The development of atherosclerotic plaques is significantly
enhanced in mice with naturally elevated plasma cholesterol levels, such as Apoe−/− or Ldlr−/− mouse
strains. In mice, TNF-α has been recognized as one of the most potent proatherogenic cytokines,
and the formation of atherosclerotic lesions was preceded by an increased expression of TNF-α, TNFR1,
and TNFR2, which were elevated even further during plaque growth [87]. Knockout of the Tnfa
gene in Apoe−/− mice fed a high-fat diet retarded the progression of plaque growth and decreased
levels of pro-atherosclerotic factors without affecting cholesterol levels [88,89]. Experiments with the
APOE*3-Leiden Tnfa−/− strain fed a high-cholesterol diet also demonstrated that TNF-α promoted
necrosis in plaque-infiltrating cells and enhanced advanced lesion formation [90]. Data obtained from
bone marrow chimeric mice suggested that TNF-α expressed by the bone marrow cells played a key
role in an Apoe−/− mouse model of atherosclerosis [91]. In line with this data, Apoe−/− mice on a high-fat,
high-cholesterol diet receiving recombinant TNF-α developed an enhanced atherosclerotic phenotype,
which could be reversed by NF-κB inhibitors [92].
In contrast to data from transgenic models, the results of the pharmacological inhibition of TNF-α in
mouse models were less consistent. It has been demonstrated that recombinant soluble TNFR1 successfully
attenuated the formation of aortic lesions in an Apoe−/− model [91]. Beneficial effects of infliximab on
endothelial reactive oxygen species (ROS) production and plaque formation were further confirmed in
Apoe−/−mice kept in hypoxia conditions and fed a high-fat diet [93]. However, in Ldlr−/−mice, monotherapy
with etanercept failed to reduce the development of atherosclerotic plaques, and the atheroprotective effect
of etanercept was observed only in combination with cholesterol-lowering drugs [94]. Instead, treatment
with anti-TNF-α monoclonal antibody CNTO5048 (neutralizing specifically murine TNF-α) surprisingly
increased plaque burden, the expression of vascular inflammatory genes, and the pro-atherogenic lipid
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profile in hypercholesterolemic Ldlr−/−mice [95]. These inconsistent findings could potentially be explained
by the involvement of mTNF-α, because most of the anti-TNF-α antibodies neutralize exclusively sTNF-α.
Indeed, the proatherogenic effect of mTNF-α has been associated with its presence on exosomes produced
by dendritic cells and the activation of the pro-inflammatory NF-κB pathway in endothelial cells [96].
Although experiments with transgenic mice expressing an exclusively non-cleavable form of mTNF-α
demonstrated the involvement of mTNF-α, these findings pointed primarily to the key role of sTNF-α in
mouse atherogenesis [97–99]. On the other hand, mice with an increased expression of mTNF-α (due to a
reduced expression of Adam17) showed enhanced macrophage adhesion and atherosclerosis in an Ldlr−/−
mouse model [98]. It should be noticed that in this model, an increased expression of mTNF-α was
associated with the constitutive activation of TNFR2 signaling. Mouse models have been also used to
elucidate the role of TNFR1 in the pathogenesis of atherosclerosis. Tnfrsf1a−/− were initially reported to
develop enhanced atherogenesis when fed an atherogenic diet [100]. However, Tnfrsf1a−/− mice on a
proatherogenic Apoe−/− background showed reduced atherosclerosis, and the data pointed to the key role
of TNFR1 expressed in arteries [101]. Summarizing, the proatherogenic role of TNF-α has been generally
confirmed in animal studies, but there is a surprisingly high discrepancy in results obtained from different
models. It seems that Apoe−/−, rather than Ldlr−/− or non-transgenic mice, represents the most relevant
animal model to study TNF-α signaling in atherosclerosis.
5.4. Myocardial Infarction
Experimental acute myocardial infarction is typically achieved by permanent or temporary
mechanical ligation of the left anterior descending coronary artery. Animals surviving this procedure
eventually develop fibrotic scars (that replaces necrotic myocardium), and their hearts show impaired
function and hemodynamic abnormalities. Published data report elevated sTNF-α levels in the serum
of post-infarcted mice and increased mTNF-α expression in the infarct and peri-infarct zones [102].
In a permanent occlusion model, Tnfa−/− mice showed a significantly smaller infarct area, decreased
expression of intercellular adhesion molecule 1 (ICAM-1), and lower numbers of heart-infiltrating neutrophils
and macrophages [103]. However, in the same model, a lack of both TNFRs led to a significant increase
in the infarction size and to an increased apoptosis of cardiomyocytes [104]. A smaller infarct size, better
cardiac function, and reduced inflammatory response were observed in Tnfa−/− mice also in a myocardial
ischemia–reperfusion injury model [105]. Similarly, the blockade of TNF-α with etanercept 10 min prior
to ischemia–reperfusion injury improved cardiac functions, reduced infarct size, and cardiomyocyte
apoptosis [106]. Moreover, a single dose of etanercept injected at the time of myocardial infarction
improved long-term cardiac function and reduced cardiac tissue remodeling in rats [107]. In another
study, pharmacological inhibitor preventing TNF-α binding to its receptor (CAS1049741-03-8) reduced
post-infarction inflammatory response but worsened cardiac function due to enhanced cardiomyocyte
apoptosis [108]. The injection of anti-TNF-α antibody 3 h prior to ischemia–reperfusion was also shown
to reduce endothelial dysfunction by reducing the production of endothelial ROS [109]. Pathogenic
processes over a long term are primary mediated by TNFR1-dependent pathways, as Tnfrsf1a−/− mice
were consistently reported to develop less impaired cardiac contractile functions and showed better
survival rates up to several weeks after infarction [110–113]. This phenotype was associated with the
reduced expression of inflammatory cytokines, matrix metalloproteinase activity, and diminished NF-κB
and MAPK activation in the cardiac tissue. Data from mice lacking an NF-κB p50 subunit confirmed the
involvement of this TNFR1-downstream pathway in the pathogenesis of myocardial infarction [114].
The pathogenic role of TNFR1 in myocardial infarction is not limited to its signaling in the heart.
Cardiovascular homeostasis is regulated by the subfornical organ located in the forebrain, which
controls cardiac sympathetic excitation. The targeted inactivation of TNFR1 in the subfornical organ
reduced left ventricular dysfunction induced by coronary artery ligation in rats [115]. Unlike TNFR1
signaling, TNFR2-dependent pathways mainly activate cardioprotective processes in the post-infarction
heart. Accordingly, Tnfrsf1b−/− mice showed exacerbated cardiomyocyte apoptosis and fibrosis as
well as worsened cardiac function and long-term survival in a permanent occlusion model [110,111].
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Of note, ischemia–reperfusion experiments on isolated hearts confirmed the deteriorating effect of
TNF-α [116] and cardioprotective role of TNFR2 on myocardial function recovery [117]. Summarizing,
mouse data underlined the activation of TNF-α signaling in the infarcted myocardium and highlighted
the counteractive effects mediated by both TNFRs.
5.5. Non-Ischemic Heart Failure Models
Non-ischemic heart diseases refer to cardiac abnormalities occurring in the absence of coronary
artery diseases. Cardiomyopathies represent the most common type of non-ischemic heart disease,
in which ventricles become enlarged and stiff. Cardiomyopathies may be caused by an abnormally
thick myocardium (hypertrophic cardiomyopathy) or by the dilatation of the ventricles (dilated
cardiomyopathy) [118]. Hypertrophic cardiomyopathy may be genetic or can be caused by chronic
hypertension or stress, and it is characterized by ineffective muscle relaxation. On the other hand,
the phenotype of dilated cardiomyopathy, which is associated with left ventricular or biventricular
dilatation and systolic and diastolic dysfunction, can be a consequence of the ongoing inflammatory
processes in the heart. Cardiomyopathies are often progressive pathologies causing not only impaired
blood pumping but also heart valve problems, blood clots, and arrhythmias, leading to heart and secondary
organ failures. There is a number of established animal models that reproduce both hypertrophic and
dilated cardiomyopathy conditions [119].
5.6. Hypertrophic Cardiomyopathy
Experimental hypertension in rodents is commonly achieved by the partial occlusion of the aorta
(transverse aortic constriction model) or by continuous infusion of the vasoconstrictor angiotensin II
using osmotic minipumps. In these models, increased blood pressure in the heart induces a compensatory
mechanism, by which the left ventricle becomes over time thicker and thereby less effective in muscle
relaxation. On the cellular level, cardiac tissue is characterized by cardiomyocyte hypertrophy and
interstitial fibrosis. Data from a mouse model of pressure overload induced by aortic banding pointed
to the active role of TNF-α–TNFR1 signaling in the development of hypertensive cardiomyopathy,
as initially suggested by the correlation between progressive hypertrophy and increasing myocardial
levels of TNF-α, TNFR1, and TACE [120,121]. In line with this suggestion, Tnfa−/− mice developed
significantly lower inflammatory response, cardiac hypertrophy, and left ventricular remodeling,
showing preserved cardiac functions in several studies [120–123]. This phenotype was attributed
to the abrogated production of superoxide in a TNF-α/PI3K-dependent manner in cardiomyocytes
and in cardiac fibroblasts [122], changes in the expression and activity of metalloproteinases [120],
decreased cardiac inflammation, and abrogated cardiomyocyte apoptosis [121]. Interestingly, in this
model of hypertension, cardiac TACE activity and TNF-α levels were controlled by tissue inhibitor of
metalloproteinase (TIMP)-3 [120]. The pathogenic mechanism is mainly mediated by TNFR1. Accordingly,
Tnfrsf1a−/− mice are partially protected from transverse aortic constriction-induced hypertrophy and
are characterized by better survival rates [124]. In the same model, mice lacking the TNFR1 adaptor
molecule TRADD also developed significantly attenuated fibrosis with better cardiac functions,
suggesting a key role of the TNFR1–TRADD-dependent cell death in hypertrophic cardiomyopathy [125].
This pathogenic TNFR1 signaling seems to be counter-regulated by TNFR2. In response to the increased
blood pressure induced by transverse aortic constriction, mice lacking Tnfrsf1b showed worsened
survival rates and increased cardiac hypertrophy, and the cardioprotective TNFR2 signaling has
been linked to its effects in mitochondria [124]. Moreover, mice with cardiac-specific TRAF2 deletion
developed exacerbated heart failure with pathological remodeling and cardiomyocyte necroptosis [30].
Similar data were obtained in another model of hypertrophic cardiomyopathy. In an angiotensin II
osmotic minipump model, Tnfa−/− and Tnfrsf1a−/−mice showed significantly attenuated phenotype [126,127].
In-depth analysis demonstrated reduced immunofibrotic changes in the myocardium of Tnfrsf1a−/−
mice, but there was no protective effect on diastolic dysfunction in this model [127]. In contrast,
Tnfrsf1b−/− mice receiving angiotensin II infusion developed fibrosis and showed only slight changes
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in expression of pro-fibrotic genes [128]. Thus, it seems that also in this model of hypertrophy, TNF-α–
TNFR1 signaling is involved in disease progression.
Cardiac hypertrophy associated with diastolic dysfunction can be alternatively induced by
the continuous delivery of β-adrenergic agonist isoproterenol. In this model, mice lacking TNFR1
developed reduced inflammatory response, but this was insufficient to protect them from isoproterenol-
induced hypertrophy, whereas mice deficient of TNFR2 showed an increased pro-inflammatory
response and exacerbated cardiac hypertrophy [129]. Of note, in vitro experiments confirmed that
TNF-α indeed could enhance isoproterenol-induced cardiomyocyte hypertrophy, but surprisingly, this
effect was completely blocked by anti-TNFR2 antibody [130].
Mice consuming increasing doses of ethanol over longer periods of time develop a specific type of
alcoholic cardiomyopathy with fibrotic and structural changes in the left ventricle. In this model, mice
showed TNFR1-dependent elevated serum levels of TNF-α, left ventricle dysfunction, and increased
cardiac ROS and pro-inflammatory cytokine production [131]. Increased TNF-α levels have been also
observed in a rat model of adriamycin-induced cardiomyopathy. Animals with higher serum TNF-α
levels showed worse heart function and increased mortality [132].
Summarizing, data from hypertrophic cardiomyopathy models suggest that targeting TNF-α indeed
might successfully prevent from disease development. It should be noted that as in other cardiovascular
diseases, pathogenic TNF-α signaling is mainly mediated by TNFR1.
5.7. Inflammatory Heart Diseases
In animal models, heart-specific inflammation is induced either by infection with cardiotropic
virus (mainly coxsackievirus B3) or by the active induction of heart-specific autoimmunity [133]. In the
infectious model, myocarditis is triggered by the immune response to the virus infecting and replicating
in cardiomyocytes, whereas in the autoimmune model, myocarditis is mainly mediated by the activated
heart-specific CD4+ T lymphocytes. Published data suggest that the TNF-α–TNFR1 axis plays an active
role in the development of myocarditis. In a coxsackievirus B3 model, Tnfa−/− and Tnfrsf1a−/− but not
Tnfrsf1b−/− mice showed strikingly reduced cardiac inflammation [134]. Interestingly, defects in TNF-α
signaling showed no effect on viral titers. In a mouse model of experimental autoimmune myocarditis
induced by immunization with cardiac myosin, TNF-α/β neutralizing antibodies delivered prior to but
not after immunization reduced the incidence of myocarditis [135]. Furthermore, Tnfrsf1a−/− mice were
completely protected from the development of myocarditis induced by immunization with cardiac
myosin or by an adoptive transfer of autoreactive T lymphocytes [136]. Although published data point
to the pathogenic role of TNF-α signaling in the development of inflammatory heart disease, it should
be noted that current knowledge is based on a few studies only and that the role of TNF-α signaling in
the transition from myocarditis to dilated cardiomyopathy remains unknown.
Table 2. Summary of phenotypes observed in animal models of cardiovascular diseases in relation to
modification of the TNF-α signaling pathway.





none Lethal myocarditis with interstitial edema [80]
none Progressive heart failure with severe LV remodeling [81]
none Calcium-dependent atrial and ventricular arrhythmias [82]
sTNFR1 overexpression Preservation of LV function [83]
Tnfrsf1a−/− Improved cardiac function, reduced mortality
[85]




none Cardiac hypertrophy without inflammation andsystolic dysfunction [86]
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Protection from atherosclerotic lesion formation, lowered
atherogenic lipid profile, decreased IL-6 levels
[99]
Exclusive expression of mTNF-α
Partial protection from atherosclerosis. Lower lipid
deposition and macrophage accumulation, no changes in




Slower plaque growth, decreased atherosclerotic markers,
no changes in cholesterol levels [88,89]
Tnfa−/− Reduced plaque growth




Tnfrsf1a−/− grafted arteries Reduced plaque growth and adhesion molecule expression [101]
Weekly infliximab injections Improved endothelial functions, reduced atheroscleroticplaques, and decreased ROS [93]
Single injection of DC-derived
mTNF-bearing exosomes





Higher number of early lesions and lower number of
advanced lesions. Decreased necroptosis and increased
apoptosis in lesion area. No changes in inflammatory





and permanent TNFR2 activation)
Faster plaque growth, enhanced macrophage adhesion,
increased macrophage, and smooth muscle proliferation [98]
Etanercept in combination with
pravastatin/saprogrelate therapy
Decrease in aortic lesion area, endothelial adhesion





Reduced plaque stability, increased vascular
pro-inflammatory gene expression, and larger plaque area [95]





Lower infarct area, less infiltrating mononuclear cells,
reduced expression of endothelial adhesion molecules at
day 1 and 7
[103]
Improved cardiac functions up to 3 days, but not at day 7 [113]
Tnfrsf1a−/−
Improved contractile functions, diminished hypertrophy
and remodeling, reduced NF-κB activation after 4 weeks [110]
Lower infarct area and fibrosis, preserved cardiac functions
at day 7 [113]
Improved contractile functions, increased survival rate after
4 weeks [111]
Protection for infarction-induced death, improved LV
functions, and decreased hypertrophy after 6 weeks [112]
Reduced mortality 24 h post infarction, lower inflammation,
and improved cardiac recovery after 28 days [123]
Pharmacological TNFR1 inactivation
in subfornical organ Reduced LV dysfunction after 4 weeks [115]
Tnfrsf1b−/−
Worsened remodeling, hypertrophy and contractile
functions, increased fibrosis and apoptosis at day 28 [110]
Worsened cardiac functions, increased infarct size,
exacerbated fibrosis at day 3 and 7 [113]
Exacerbated hypertrophy, fibrosis, ventricular dilatation,
and dysfunction after 4 weeks [111]
Increased mortality during the first 7 days, reduced number
of functional blood vessels in infarct area after 28 days [123]
Daily monoclonal anti-TNF-α antibody
administration during the first week
after myocardial infarction
Reduced inflammation, worsened cardiac functions,
inhibited autophagy and increased apoptosis in
cardiomyocytes after 1, 2, 3, and 4 weeks
[108]
Single etanercept injection directly
after myocardial infarction
Reduced inflammation, improved remodeling,
and preserved LV functions after 4 days [107]
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Lower infarct area, improved cardiac functions, reduced
cardiac NF-κB activation measured 120 min
from reperfusion
[105]
Etanercept administration 10 min prior
to myocardial infarction
Lower infarct area, improved cardiac functions, 3 h, 24 h,
or 14 days after reperfusion [106]
Anti-mouse TNF-α antibody injection
3 h prior myocardial infarction
Preserved endothelial functions, reduced endothelial





Reduced inflammatory response, decreased hypertrophy,
improved cardiac functions [121]
Tnfa−/−Timp3−/−
Attenuated LV dilation, improved cardiac functions,
increased survival after 7 weeks. Complete prevention of




Improved cardiac functions, suppression of MMPs
expression, reduction in superoxide production [122]
Tnfrsf1b−/−
Increased survival rates, decreased hypertrophy, improved
mitochondrial functions [124]
Tradd−/−
Reduced hypertrophy with improved cardiac functions,
attenuated TAK1/p38 MAPK phosphorylation [125]
Tnfrsf1a−/−Tnfrsf1b−/−
Increased mortality, hypertrophy, and mitochondrial
DNA damage [124]
Traf2−/−





Tnfa−/− Reduced hypertrophy and hypertension [126]
Tnfrsf1a−/−
Slower progression of hypertrophy, reduced fibrosis and
immune response [127]
Tnfrsf1a−/−
No effect on early inflammatory phase, increased uptake of
bone marrow-derived fibroblasts progenitors and
exacerbated fibrosis
[128]





Reduced inflammatory response at day 1, unchanged
hypertrophy at day 7
[129]
Tnfrsf1b−/−
Increased inflammatory response at day 1, exacerbated
hypertrophy at day 7
Alcoholic
cardiomyopathy Tnfrsf1a
−/− Preserved LV functions, decreased ROS in LV, lower serum





Tnfa−/− Reduced myocarditis, no changes in virus titers
[134]Tnfrsf1a−/− Reduced myocarditis, no changes in virus titers





Anti-TNF-α/β before immunization Reduced myocarditis
[135]
Anti-TNF-α/β after immunization Unaffected myocarditis






Tnfrsf1a−/− Protection from myocarditis
LDL: low-density lipoprotein LV: left ventricular, MMP: matrix metalloproteinase, ROS: reactive oxygen species,
Timp3−/−: metalloproteinase inhibitor 3 knockout, Tnfa−/−: tumor necrosis factor-α knockout, Tnfrsf1a−/−: TNFR1
knockout, Tnfrsf1b−/−: TNFR2 knockout, TRADD−/−: tumor necrosis factor receptor type 1-associated death domain
protein knockout.
6. Cellular and Molecular Mechanisms of TNF-α Signaling in Cardiovascular Diseases
The heart is made up of three main cell types: cardiomyocytes, cardiac microvascular endothelial
cells, and cardiac stromal cells (mainly fibroblasts). In addition, heart-resident macrophages represent
a small but important cell population in the healthy heart. Furthermore, in response to injury, cardiac
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tissue is infiltrated by immune cells, such as inflammatory monocytes and lymphocytes. It should be
noted that TNF-α can be produced by many cardiac cell types, but immune cells seem to represent
a particularly important source of this cytokine in cardiac pathology. TNF-α signaling controls
many biological processes ranging from pro-inflammatory and proapoptotic to regenerative and
cardioprotective (Figure 2). The actual effect of TNF-α depends not only on the cell type and activation
of other molecular pathways, but also on expression of inducible TNFR2 (TNFR1 is generally stably
expressed in nearly all cell types). As demonstrated in animal models, the deleterious effects of TNF-α
are mainly mediated by the prolonged or excessive activation of TNFR1, while the activation of TNFR2











Figure 2. Biological effects mediated by TNFR1 and TNFR2 in main cellular components of the heart.
ECM: extracellular matrix, LDL: low-density lipoprotein, MMP: matrix metalloproteinase, NO: nitric oxide.
6.1. Pathogenic Mechanisms
The activation of endothelial cells represents one of the best described pro-inflammatory mechanisms.
Endothelial cells respond to TNF-α by an increased expression of adhesion molecules, which control the
rolling and adhesion of inflammatory immune cells into the tissue. In this mechanism, both TNFRs are
also critically engaged in the process of diapedesis [137]. TNF-α is also known to increase ROS levels and
decrease nitric oxide production in blood vessels, which can lead to endothelial dysfunction: an initial
step in atherogenesis [138]. In this process, TNF-α-induced ROS production depends on the activation of
NADH oxidase [139,140]. TNF-α contributes also to the development of atherosclerotic plaques through
an increase of LDL transcytosis in endothelial cells [91,92] and by regulating the activity of macrophage
scavenger receptor and foam cell formation [141]. TNFR2 signaling contributes also to deleterious effects
by increasing macrophage and smooth muscle proliferation [98].
In cardiomyocytes TNF-α triggers a hypertrophic response and induces apoptosis [131]. Endogenous
TNF-α contributes to increased protein synthesis and hypertrophy [142] through the NF-κB-mediated
production of ROS [143]. In cardiomyocytes, this process is dependent on TNFR1 activation, but it also
negatively regulates calcium handling and cell contractility [144]. Moreover, TNF-α-induced superoxide
production was shown to depend on NADPH oxidase activation by PI3K and to control the secretion of
several matrix metalloproteinases (MMPs) [122]. Oxidative stress mediated by TNF-α is also responsible
for mitochondrial DNA damage through the sphingomyelin–ceramide signaling pathway [145], which was
also shown to induce apoptosis in cardiomyocytes [146]. TNFR1 promotes also cardiomyocyte apoptosis
independently of NF-κB through RIP1–RIP3–MLKL axis activation by apoptosis signal-regulating kinase
1 (ASK1) [20,30].
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Cardiac fibroblasts represent another heart-resident cell type that can be activated by TNF-α.
In response to TNF-α, cardiac fibroblasts contribute to the inflammatory cascade by secreting monocyte
chemoattractant proteins (MCP)-1 and MCP-3, which control monocyte recruitment but also positively
regulate TNF-α production [147]. Furthermore, TNF-α mediates ROS production and MMP secretion in
cardiac fibroblasts via the activation of PI3Kγ [122]. TNF-α contributes to hearts fibrosis also by stimulating
cardiac fibroblasts proliferation and fibronectin deposition [148]. Moreover, TNF-α induces MMP9 production
and promotes the transition of cardiac fibroblasts into pathogenic myofibroblasts [149]. Excessive collagen
deposition and the expression of pro-fibrotic genes in these cells leading to pathological heart remodeling
is controlled by TNFR1 [128,149]. TNFR1 is also important to induce fibroblast maturation from
myeloid cells [150]. All these data demonstrate a wide spectrum of pathogenic effects of TNF-α in all
cardiac cell types.
6.2. Cardioprotective Mechanisms
Most of the cardioprotective mechanisms are mediated by TNFR2. It seems that one of the most
important effects of TNFR2-dependent signaling is to suppress activation of the pathogenic TNFR1
downstream pathways. It has been observed that in the absence of TNFR2, there is an increased
activity of TNFR1 downstream effector molecules NF-κB [110] and MAPK p38 [129] as well as an
increased production of pro-inflammatory cytokines IL-1β and IL-6 [111]. The TNFR2 cardioprotective
mechanism has been described to counter-regulate the deleterious effects of TNFR1-mediated signaling
in cardiomyocytes. Accordingly, the activation of TNFR2 protected cardiomyocytes from apoptosis
and promoted cell cycle entry by activating endothelial/epithelial tyrosine kinase (ETK) [20], enhanced
resistance to oxidative stress [130,144], and mediated positive calcium transient [144]. Of interest,
TNFR2 was also shown to be critically involved in the differentiation of cardiomyocytes from stem cells
in vitro [151] and in promoting cell cycle entry in resident cardiac stem cells [152]. Furthermore, TNFR2
signaling plays an important role in immunosuppression. In particularly, the activation of TNFR2 on
regulatory T cells stimulated their expansion [153] and suppressed effector T cell differentiation [31].
TNFR2 signaling plays also a crucial role in the recruitment of myeloid suppressor cells [154], which
exert cardioprotective functions in heart failure [155]. It should be noted that the immunomodulatory
effect of TNF-α in heart failure is not well understood, mostly because of its involvement in the
activation of endothelial cells and pro-inflammatory role during the early inflammatory phase.
7. Clinical Perspectives
TNF-α is undoubtedly an important pro-inflammatory cytokine playing a key role during the early
inflammatory phase. Clinical studies and data from animal models confirmed that TNF-α enhanced the
development of a number of cardiovascular pathologies. However, preventive anti-TNF-α therapy would
not be recommended due to side effects and economic reasons. Instead, such targeted immunomodulatory
therapeutic intervention was considered in heart failure patients, but the failure of anti-TNF-α therapy
could be explained by the cardioprotective properties of TNF-α in the failing heart. Currently, our
knowledge on the beneficial activity of TNF-α is limited; therefore, more experimental research is
needed to uncover these processes and the underlying mechanisms. Available data suggest that most
of the cardioprotective activity is mediated by TNFR2, whereas the activation of TNFR1 initiates
pathogenic processes. So far, most of these findings have been obtained in mouse models using
transgenic mice lacking one or the other TNFR. In the next step, targeting these receptors, either by
blocking TNFR1 or activating TNFR2, should be performed pharmacologically. The development of
drugs selectively targeting TNFRs, rather than blocking TNF-α activity, might represent a novel and
more effective therapeutic concept in the treatment of heart disease.
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